Skip to main content
Top
Published in: The European Journal of Health Economics 2/2007

01-06-2007 | Original paper

Pharmacoeconomic studies in Italy: a critical review of the literature

Authors: D. Cornago, L. Li Bassi, P. De Compadri, L. Garattini

Published in: The European Journal of Health Economics | Issue 2/2007

Login to get access

Abstract

To assess the state of pharmacoeconomics in Italy we reviewed all the original studies published by Italian authors in national and international journals from January 1994 to December 2003. We selected 70 articles and broadly assessed 92 economic evaluations (EEs) since some articles contained multiple analyses. We adopted common analysis criteria to allow methodological comparison of the studies. The variables investigated can be grouped into three categories: general methods, costs, and consequences. To further assess the quality of the EEs, we decided to rank them according to criteria of both clinical and economic good practice. Then, to complete our critical evaluation, we analysed whether sponsorship might have somehow affected the results. Our analysis seems to support the widespread scepticism of the Italian NHS decision-makers towards pharmacoeconomic studies, whose results seem to be biased by flawed methods and sponsors’ interference with results.
Literature
1.
go back to reference Drummond, M.F., Brown, R., Fendrick, A.M., et al.: Use of pharmacoeconomics information report of the ISPOR task force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 6(4), 407–416 (2003)CrossRef Drummond, M.F., Brown, R., Fendrick, A.M., et al.: Use of pharmacoeconomics information report of the ISPOR task force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 6(4), 407–416 (2003)CrossRef
2.
go back to reference Drummond, M.F. Jönsson, B., Rutten, H.F.F.: The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 40, 199–215 (1997)CrossRef Drummond, M.F. Jönsson, B., Rutten, H.F.F.: The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 40, 199–215 (1997)CrossRef
3.
go back to reference Henry, D., Lang, D.: Published pharmacoeconomic analyses: science or marketing? Intern. Med. J. 33(9–10), 403–404 (2003)CrossRef Henry, D., Lang, D.: Published pharmacoeconomic analyses: science or marketing? Intern. Med. J. 33(9–10), 403–404 (2003)CrossRef
4.
go back to reference Drummond, M.F.: Economic evaluation of pharmaceuticals: science or marketing? Pharmacoeconomics 1(1), 8–13 (1992)CrossRef Drummond, M.F.: Economic evaluation of pharmaceuticals: science or marketing? Pharmacoeconomics 1(1), 8–13 (1992)CrossRef
5.
go back to reference Drummond, M.F., Cooke, J., Walley, T.: Economic evaluation under managed competition: evidence from the U.K. Soc. Sci. Med. 45(4), 583–595 (1997)CrossRef Drummond, M.F., Cooke, J., Walley, T.: Economic evaluation under managed competition: evidence from the U.K. Soc. Sci. Med. 45(4), 583–595 (1997)CrossRef
6.
go back to reference Drummond, M.F.: A reappraisal of economic evaluation of pharmaceuticals: science or marketing? Pharmacoeconomics 14(1), 1–9 (1998)CrossRef Drummond, M.F.: A reappraisal of economic evaluation of pharmaceuticals: science or marketing? Pharmacoeconomics 14(1), 1–9 (1998)CrossRef
7.
go back to reference Hill, S.R., Mitchell, A.S., Henry, D.A.: Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian pharmaceutical benefits scheme. JAMA 283(16), 2116–2121 (2000)CrossRef Hill, S.R., Mitchell, A.S., Henry, D.A.: Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian pharmaceutical benefits scheme. JAMA 283(16), 2116–2121 (2000)CrossRef
8.
go back to reference Laupacis, A.: Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they right ones? Can. Med. Ass. J. 166, 44–47 (2002) Laupacis, A.: Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they right ones? Can. Med. Ass. J. 166, 44–47 (2002)
9.
go back to reference Hoffmann, C., Graf von der Schulemburg, J.M.: The influence of economic evaluation studies on decision making. A European survey. The EUROMET group. Health Policy 52(3), 179–192 (2000)CrossRef Hoffmann, C., Graf von der Schulemburg, J.M.: The influence of economic evaluation studies on decision making. A European survey. The EUROMET group. Health Policy 52(3), 179–192 (2000)CrossRef
10.
go back to reference Ijzerman, M.J., Reuzel, R.P., Severens, H.L.: Pre-assessment to assess the match between cost–effectiveness results and decision makers’ information needs: an illustration using two cases in rehabilitation medicine in The Netherlands. Int. J. Technol. Assess. 19(1), 17–27 (2003)CrossRef Ijzerman, M.J., Reuzel, R.P., Severens, H.L.: Pre-assessment to assess the match between cost–effectiveness results and decision makers’ information needs: an illustration using two cases in rehabilitation medicine in The Netherlands. Int. J. Technol. Assess. 19(1), 17–27 (2003)CrossRef
11.
go back to reference Hoffman, C., Stoykova, B.A., Nixon, J., et al.: Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities. Value Health 5(2), 71–78 (2002)CrossRef Hoffman, C., Stoykova, B.A., Nixon, J., et al.: Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities. Value Health 5(2), 71–78 (2002)CrossRef
12.
go back to reference Spath, H.M., Charavel, M., Morelle, M., Carrère, M.O.: Formulary decision-making in public hospitals and private clinics in France: the role of pharmacoeconomic information. J. Econ. Med. 22(7–8), 347–354 (2004) Spath, H.M., Charavel, M., Morelle, M., Carrère, M.O.: Formulary decision-making in public hospitals and private clinics in France: the role of pharmacoeconomic information. J. Econ. Med. 22(7–8), 347–354 (2004)
13.
go back to reference France, G., Taroni, F.: The evolution of health-policy making in Italy. J. Health Polit. Policy Law 30(1–2), 169–87 (2005)CrossRef France, G., Taroni, F.: The evolution of health-policy making in Italy. J. Health Polit. Policy Law 30(1–2), 169–87 (2005)CrossRef
14.
go back to reference Drummond, M.F., Dubois, D., Garattini, L., et al.: Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value Health 2(5), 323–332 (1999)CrossRef Drummond, M.F., Dubois, D., Garattini, L., et al.: Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value Health 2(5), 323–332 (1999)CrossRef
15.
go back to reference Garattini, L., De Compadri, P., Clemente, R., Cornago, D.: Economic evaluations in Italy: a review of the literature. Int. J. Technol. Assess. 19(4), 685–737 (2003) Garattini, L., De Compadri, P., Clemente, R., Cornago, D.: Economic evaluations in Italy: a review of the literature. Int. J. Technol. Assess. 19(4), 685–737 (2003)
16.
go back to reference De Pouvourville, G., Ulmann, P., Nixon, J., et al.: The diffusion of health economics knowledge in Europe. The EURONHEED (European network of health economic evaluation databases) project. Pharmacoeconomics 23(2), 113–120 (2005)CrossRef De Pouvourville, G., Ulmann, P., Nixon, J., et al.: The diffusion of health economics knowledge in Europe. The EURONHEED (European network of health economic evaluation databases) project. Pharmacoeconomics 23(2), 113–120 (2005)CrossRef
17.
go back to reference Buxton, M.J., Drummond, M.F., Van Hout, B.A., et al.: Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 6(3), 217–227 (1997)CrossRef Buxton, M.J., Drummond, M.F., Van Hout, B.A., et al.: Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 6(3), 217–227 (1997)CrossRef
18.
go back to reference Drummond, M.F., Davis, L.: Economic analysis alongside clinical trials: revisiting the methodological issues. Int. J. Technol. Assess. 7(4), 561–573 (1991)CrossRef Drummond, M.F., Davis, L.: Economic analysis alongside clinical trials: revisiting the methodological issues. Int. J. Technol. Assess. 7(4), 561–573 (1991)CrossRef
19.
go back to reference Garattini, L., Grilli, R., Scopelliti, D., et al.: A proposal for Italian guidelines in pharmacoeconomics. PharmacoEconomics 7(1), 1–6 (1995)CrossRef Garattini, L., Grilli, R., Scopelliti, D., et al.: A proposal for Italian guidelines in pharmacoeconomics. PharmacoEconomics 7(1), 1–6 (1995)CrossRef
20.
go back to reference Taroni F.: DRG/SDO e Nuovo Sistema di Finanziamento Degli Ospedali. Il Pensiero Scientifico Editore, Roma (1996) Taroni F.: DRG/SDO e Nuovo Sistema di Finanziamento Degli Ospedali. Il Pensiero Scientifico Editore, Roma (1996)
21.
go back to reference Rabeneck, L., Viscoli, C.M., Horwitz, R.I.: Problems in the conduct and analysis of randomized clinical trias. Are we getting the right answers to the wrong questions? Arc. Intern. Med. 152(3), 507–512 (1992)CrossRef Rabeneck, L., Viscoli, C.M., Horwitz, R.I.: Problems in the conduct and analysis of randomized clinical trias. Are we getting the right answers to the wrong questions? Arc. Intern. Med. 152(3), 507–512 (1992)CrossRef
22.
go back to reference Sacks, H.S., Terrier, J., Reitmann, D., Ancona-Berck, V.A., Chalmers, T.C.: Meta-analyses of randomized controlled trials. N. Engl. J. Med. 316(8), 450–455 (1987)CrossRef Sacks, H.S., Terrier, J., Reitmann, D., Ancona-Berck, V.A., Chalmers, T.C.: Meta-analyses of randomized controlled trials. N. Engl. J. Med. 316(8), 450–455 (1987)CrossRef
23.
go back to reference Egger, M., Smith, G.D., Phillips, A.N.: Meta-analysis. Princ. proced. BMJ 315, 1533–1537 (1997) Egger, M., Smith, G.D., Phillips, A.N.: Meta-analysis. Princ. proced. BMJ 315, 1533–1537 (1997)
24.
go back to reference Smith, G.D., Phillips, A.N.: Meta-analysis. Beyond the grand mean? BMJ 315, 1610–1614 (1997) Smith, G.D., Phillips, A.N.: Meta-analysis. Beyond the grand mean? BMJ 315, 1610–1614 (1997)
25.
go back to reference Crombie, I.K.: The Pocket Guide to Critical Appraisal. BMJ Publishing group, London (1996) Crombie, I.K.: The Pocket Guide to Critical Appraisal. BMJ Publishing group, London (1996)
26.
go back to reference Drummond, M.F., O’Brien, B, Stoddart, G.L., Torrance, G.W.: Methods for the Economic Evaluation of Health Care Programmes. Oxford Medical Publications, Oxford (1997) Drummond, M.F., O’Brien, B, Stoddart, G.L., Torrance, G.W.: Methods for the Economic Evaluation of Health Care Programmes. Oxford Medical Publications, Oxford (1997)
27.
go back to reference Krimsky, S.: Conflict of interest and cost–effectiveness analysis. JAMA 282(15), 1474–1475 (1999)CrossRef Krimsky, S.: Conflict of interest and cost–effectiveness analysis. JAMA 282(15), 1474–1475 (1999)CrossRef
28.
go back to reference Morgan, S., Barer, M., Evans, R.: Health economists meet the fourth tempter: drug dependency and scientific discorse. Health Econ. 9, 659–667 (2000)CrossRef Morgan, S., Barer, M., Evans, R.: Health economists meet the fourth tempter: drug dependency and scientific discorse. Health Econ. 9, 659–667 (2000)CrossRef
29.
go back to reference Rennie, D., Luft, H.: Pharmacoeconomic analysis: making them transparent, making them credible. JAMA 283(16), 2158–2160 (2000)CrossRef Rennie, D., Luft, H.: Pharmacoeconomic analysis: making them transparent, making them credible. JAMA 283(16), 2158–2160 (2000)CrossRef
30.
go back to reference De Compadri, P., Cornago, D., Garattini, L.: The Influence of Economic Evaluations Studies on Decision-Making in Italy. In: Eberhardt, S., Stoklossa, C., Graf von der Schulenburg, J.M.: (eds) EUROMET 2004: The Influence of Economic Evaluations on Decision Making. IOS Press, Amsterdam (2005) De Compadri, P., Cornago, D., Garattini, L.: The Influence of Economic Evaluations Studies on Decision-Making in Italy. In: Eberhardt, S., Stoklossa, C., Graf von der Schulenburg, J.M.: (eds) EUROMET 2004: The Influence of Economic Evaluations on Decision Making. IOS Press, Amsterdam (2005)
Metadata
Title
Pharmacoeconomic studies in Italy: a critical review of the literature
Authors
D. Cornago
L. Li Bassi
P. De Compadri
L. Garattini
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 2/2007
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-006-0011-8

Other articles of this Issue 2/2007

The European Journal of Health Economics 2/2007 Go to the issue

Pricing and Reimbursement Systems in Europe

Discussion point: should governments buy drug patents?